Strong Revenue GrowthSuven reported very strong top-line expansion (notable increase from 2024 to 2025). Durable revenue growth indicates expanding CDMO program wins and higher volumes, which supports capacity utilization and long-term contract conversion over the next several quarters.

Solid Balance Sheet / Low LeverageA low-debt, strong-equity balance sheet and healthy ROE give Suven financial flexibility to fund capex, weather project timing variability and pursue incremental capacity or R&D investments without materially increasing liquidity risk.

CDMO/CRAMS Business ModelThe contract development and manufacturing model yields multi-stage revenue (development fees then commercial supply). This creates durable client relationships, repeat manufacturing demand and structural revenue visibility as programs advance toward commercialization.

Bears Say

Declining Net IncomeNet income fell despite revenue gains, implying margin compression from higher operating costs or pricing pressure. If costs remain elevated or competition intensifies, sustained profitability could weaken, reducing retained earnings available for reinvestment.

Weakened Free Cash FlowFCF declined as operating cash generation weakened while capex rose. Lower free cash constrains the company's ability to self-fund capacity expansion, reduce leverage or return capital, increasing reliance on internal improvements or external funding if trends persist.

Revenue Reliant On Customer Program ProgressionSuven's revenue materially depends on customers advancing programs from development to commercial supply. Program delays, cancellations or concentration among few clients can sharply reduce volumes and revenue visibility, posing a persistent operational risk.

Suven Pharmaceuticals Ltd. News

Cohance Lifesciences to Engage Investors at IIFL and Kotak Conferences in February 2026

Suven Pharmaceuticals Ltd. ( ($IN:COHANCE) ) just unveiled an announcement. Cohance Lifesciences Limited has announced that its management...

13d ago

COHANCE FAQ

What was Suven Pharmaceuticals Ltd.’s price range in the past 12 months?

Suven Pharmaceuticals Ltd. lowest stock price was ₹298.00 and its highest was ₹1246.85 in the past 12 months.

What is Suven Pharmaceuticals Ltd.’s market cap?

Suven Pharmaceuticals Ltd.’s market cap is ₹116.19B.

When is Suven Pharmaceuticals Ltd.’s upcoming earnings report date?

Suven Pharmaceuticals Ltd.’s upcoming earnings report date is May 28, 2026 which is in 84 days.

How were Suven Pharmaceuticals Ltd.’s earnings last quarter?

Suven Pharmaceuticals Ltd. released its earnings results on Feb 12, 2026. The company reported ₹0.975 earnings per share for the quarter, missing the consensus estimate of ₹2.693 by -₹1.718.

Is Suven Pharmaceuticals Ltd. overvalued?

According to Wall Street analysts Suven Pharmaceuticals Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Suven Pharmaceuticals Ltd. pay dividends?

Suven Pharmaceuticals Ltd. pays a Notavailable dividend of ₹5 which represents an annual dividend yield of N/A. See more information on Suven Pharmaceuticals Ltd. dividends here

What is Suven Pharmaceuticals Ltd.’s EPS estimate?

Suven Pharmaceuticals Ltd.’s EPS estimate is 1.58.

How many shares outstanding does Suven Pharmaceuticals Ltd. have?

Suven Pharmaceuticals Ltd. has 382,567,140 shares outstanding.

What happened to Suven Pharmaceuticals Ltd.’s price movement after its last earnings report?

Suven Pharmaceuticals Ltd. reported an EPS of ₹0.975 in its last earnings report, missing expectations of ₹2.693. Following the earnings report the stock price went down -1.253%.

Which hedge fund is a major shareholder of Suven Pharmaceuticals Ltd.?

Currently, no hedge funds are holding shares in IN:COHANCE

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Suven Pharmaceuticals Ltd.

Cohance Lifesciences Limited is a Hyderabad-based pharmaceutical company specializing in contract development and manufacturing (CDMO) services, active pharmaceutical ingredients (APIs), and specialty chemicals. The company was formerly known as Suven Pharmaceuticals Limited and underwent a rebranding following its merger with Cohance Lifesciences, effective May 1, 2025.